Login to Your Account



Phase III Plans in the Works

Cytokinetics’ Phase II HF Data: Traders Skeptical, Amgen Not

By Randy Osborne
Staff Writer

Tuesday, September 3, 2013
Cytokinetics Inc. and licensor Amgen Inc. will wait until a Phase II study in chronic heart failure with orally given omecamtiv mecarbil generates data to decide the fate of the compound, which fizzled in a Phase II trial testing the intravenous form of the cardiac myosin activator against acute heart failure.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription